Prostate Cancer, Prostate Neoplasm
Conditions
Keywords
Prostate cancer, [18F]FPSMA-1007, mpMRI
Brief summary
The diagnostic tools for detecting patients with early prostate cancer are limited due to poor diagnostic performance. The positron emission tomography (PET) combination with the diagnostic radiopharmacy is a non-invasive tool to provide the molecular imaging of the whole body and offer more comprehensive physiological information and then can raise the diagnostic performance. Prostate-specific membrane antigen (PSMA)-targeting pharmaceuticals have been regarded as the most promising diagnostic tool to diagnose patients with prostate cancer. Currently, the 18F-PSMA-1007 as PSMA-targeting 18F-radiolabeled pharmaceuticals have developed and successfully used in patients with intermittent- and high-risk prostate cancer or recurrent prostate cancer. The study aims to understand the diagnostic performance of 18F-PSMA-1007 PET/CT in different-stage prostate cancer patients by initiating the first multicenter clinical trial of 18F-PSMA-1007 in Taiwan.
Interventions
DRUG18F-PSMA-1007
18F-PSMA-1007 PET/CT
Sponsors
ABX advanced biochemical compounds GmbH
Primo Biotechnology Co., Ltd
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
MALE
Age
20 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
1. The participants are male adults over 20 years old. 2. The participants are suspected prostate cancer patients by a serum PSA value of 4-20 ng/ml or a serum PSA value of \< 4ng/ml but noted abnormal lesion by DRE. 3. The participants agree to receive TRUS Bx or mpMRI fusion Bx examination. 4. The participants are the first time to receive a prostatic biopsy.
Exclusion criteria
1. The participants are diagnosed with prostate cancer before this study. 2. The participants have received any related treatment for prostate cancer. 3. The participants have chronic prostatitis. 4. The participants' serum hemoglobin lowers than 10 mg/dl within 1 month. 5. The participants' serum platelet lowers than 15 103/uL within 1 month. 6. The participants' serum prothrombin time (PT) is prolonged longer than 1.2-fold within 1 month. 7. The participants' serum active partial prothrombin time (aPPT) is prolonged longer than 45 seconds within 1 month. 8. The participants have hemorrhagic disease such as Hemophilia, Von Willebrand disease, thrombocytopenia, systemic Lupus Erythematosus, etc. within 6 months. 9. The participants have conditions of poor immunity status such as HIV infection, receiving treatment for other cancer, DM poor control, use of immunomodulator (ex. steroid, etc.) within 6 months. 10. The participants have hypertension poor control that is BP cannot be controlled lower than 140/90mmHg whether or not taking medication within 6 months. 11. The participants have suffered from CVA including infarctions and hemorrhages within 6 months. 12. The participants have suffered from angina including stable and unstable types within 6 months. 13. The participants have suffered from arrythmia poor control within 6 months. 14. The participants have suffered from liver dysfunction such as AST/ALT ratio \>2、total bilirubin \>1.5 mg/dL within 6 months. 15. The participants are allergic to any radiopharmaceutical or imaging agent. 16. The participants suffered stage IV chronic kidney disease (eGFR\<30 mL/min/1.73 m2) within 6 months 17. The participants suffered acute kidney injury within 6 months. 18. The participants are absolute and relative contraindications to MRI examination.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Diagnostic Performance | 7-14 days after PET/CT | Sensitivity, Specificity, NPV, PPV |
Countries
Taiwan
Contacts
Primary ContactYating Huang
Outcome results
None listed